Lifecore Biomedical approves FY2026 bonus plan for executives with EBITDA, revenue targets

LIFECORE BIOMEDICAL, INC. DE

Board approved FY2026 cash bonus plan for CEO Paul Josephs (100% target), CFO Ryan Lake (60%), and CAO Thomas Salus (50%).
Bonus weighted 80% to Adjusted EBITDA and development revenue; max payout 200% of target; no bonus if minimum EBITDA unmet.
Individual performance goals and company business goals each weighted 10%.
Salus receives 125% of any bonus earned per employment agreement; all bonuses subject to clawback policy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.